U.S. FDA Panel Blesses Otsuka’s Hyponatremia Drug
This article was originally published in PharmAsia News
Executive Summary
The fate of Otsuka Pharmaceutical's Samska may have become somewhat clearer June 25, when a U.S. FDA advisory panel voted to recommend approval of the compound for hyponatremia, or subnormal sodium in the blood
You may also be interested in...
Otsuka’s Novel Samska Gets U.S. Advisory Committee Review
U.S. FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka Pharmaceutical's hyponatremia drug Samska (tolvaptan) for approval in patients with hypervolemic and euvolemic hyponatremia.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).